Great Bay Bio Adds Two Industry Leaders to Advisory Board

HONG KONG, CHINA -�Media
OutReach - 12 August 2019 – Great Bay Bio, a leading AI biotechnology company dedicated to big
data-driven CMC (Chemistry Manufacturing and Controls) development of innovative
biologics, is pleased to announce the establishment of its 3D Advisory Board.
The board of directors eagerly welcome two top industry elites, Dr. Katie Su
and Mr. Aaron Wang, to the company. They will cooperate with the board and advise
the senior management team on a range of company matters including, strategic
positioning, product portfolio composition, technical troubleshooting, and general
management. More importantly, the 3D Advisory Board will bring a series of
forward-looking concepts from both commercial and scientific arenas, to propose
new and efficient solutions to market problems. The establishment of the 3D Advisory
Board is of great significance to the company’s value proposition. Great Bay
Bio’s mission is to “Face Future Challenges
with 3D Innovation“. By combining three verticals of innovation “business foresight + science-based
foundation + technology driven“, new breakthroughs can be hatched. Currently,
the company will form three separate sub-committees (Business, Science and Technology)
to provide a solid foundation for Great Bay Bio’s mission and, ultimately reach
the company’s vision of “Making
Biologics Development Easy For Everyone“.

Brief
Introduction of Members for Advisory Board

Dr. Katie (Jing)
Su, who joins the Science Sub-Committee of the
3D Advisory Board, has more than 20 years of management and operation
experience for novel drug research and development in the biopharmaceutical
industry. She is currently serving as the President and Head of Novo Nordisk
R&D Center in China. Previously, she acted as the Chief Operating Officer
of GlaxoSmithKline R&D Center in China. Dr. Su was responsible for
formulating the development strategy and daily operation management of top
research centers endorsed by different famous Pharmaceutical brands, working
closely with the site leaders from various functions to drive business
priorities. Earlier, Ms. Su led the establishment of a brand-new research unit
of excellence in biologics discovery and engineering in Novo Nordisk China and attended
as the Head of the Department and Vice- President of global R&D. With her
solid scientific research capacity, she led the local team to excel in the
global effort on clinical candidate development in metabolic diseases,
hemophilia, autoimmune and cancer immunotherapy. At the same time, Dr. Su has
also established the world’s leading frontier platforms for identifying novel
drug targets and therapeutic candidates. Katie received a Bachelor Degree in
Medicine, School of Medicine, Peking University, Beijing, China; a Master
Degree in Business Administration, Beijing International MBA Program (BiMBA),
Peking University, China; a Doctorate Degree in Pharmacology, New York
University Medical Center, New York, US

Mr. Aaron
(Yiran) Wang, who joins the Business Sub-Committee of
the 3D Advisory Board, is currently an Investment Vice President in one of the
top venture capital funds in the world, primarily covering Greater China. Prior
to his role in the fund, Mr. Wang was an entrepreneur, engineer and investor
with multinational working experience across Beijing and San Francisco Bay Area.
He has obtained a Bachelor of Science degree in Electrical Engineering from
Peking University, a Master of Science degree in Electrical Engineering from
University of Michigan-Ann Arbor and a Master of Business Administration degree
from Harvard University.

On the establishment of the 3D Advisory Board and
the addition of the two industry elites, Mr.
Kingsley Leung, Chairman and Co-founder of Great Bay Bio, said: “The
arrival of Dr. Su and Mr. Wang is undoubtedly one of the most important
milestones of Great Bay Bio. I am very grateful and honored to have such
high-caliber and brilliant individuals become the first members of the Advisory
Board. One school of thought of innovation is Recombinant Innovation; the idea in which innovation breakthrough
does not come from facile forms of creativity or out-of-the-box thinking, but
from combining old ideas together to form new ones that fit the context of
need. Actually many of today’s innovation follows this school of thought, such
as the first smartphone; a combination of “older” innovation from different
fields and disciplines to form a world-changing device. We believe that the
best innovation comes from collaboration between people from different
backgrounds and expertise, and this is why we have structured our Advisory
Board this way. The challenge of making traditional high-cost CMC cheap is a difficult
one to solve, and that is why we believe Recombinant Innovation is our best
shot of tackling it.”

About Great Bay Bio

Headquartered
in Hong Kong, the CMC/CDMO platform of Great Bay Bio was established in 2002,
where originally more than 100 million yuan was invested to build a national
level CMC platform. The CMC/CDMO platform has independent and integrated technology
platforms for drug R&D and large-scale preparation. The company has a
strong existing track record of developing customized CMC packages for biologic
products, some of which are national class I projects of innovative biological new
drugs that have already reached NDA stage.

Great Bay Bio
is leveraging on its established platform to develop a new vertical in CMC.
Specifically, Great Bay Bio strives to utilize AI and other cutting-edge
technologies to shorten CMC development timelines, lower cost, and increase
efficiency of CMC. With such a platform, it could expand and acquire new
customer base, and brings fundamental changes to drug development, and
ultimately benefiting society and patients.

The platform
has been recognized and certificated as “Patent Fostering
Enterprise”, “Patent Pilot Enterprise”, “National High-tech
Enterprise”, “Dongguan New R&D Institution”, “Guangdong
Top Ten Foreign-funded R&D Center” and “Guangdong Genetically
Pharmaceutical Engineering Research Center”. Since 2006, it has undertaken
a number of government projects and obtained crucial breakthroughs in key areas
of Guangdong and Hong Kong. More than 20 million yuan have been received from
the government to support numerous provincial and national projects, such as
“National Major New Drug Innovation”.

The CMC platform
encompasses an area of over 3100 square meter, and has a whole set of advanced
biopharmaceutical research and development hardware, with key equipment from world-class
brands such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot
workshop is designed strictly in accordance with cGMP requirements, with cleanroom
standards of C-level and partial A-level.